From:  Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
 

SEC analysis of three different ADCs

ADCsAggregation
Trastuzumab0.4%
T-DM11.4%
Trastuzumab-MCC-maytansinoid (DAR = 4.1)0.7%
Trastuzumab-MC-VC-PAB-MMAE (DAR = 2.0)0.5%
Trastuzumab-MC-VC-PAB-MMAE (DAR = 4.0)0.5%
Return to article view